Thrombophilia
MONDO:0002305A condition characterized by an abnormally high level of thrombi. Causes include thrombotic thrombocytopenic purpura, disseminated intravascular coagulation, bone marrow disorders, and antiphospholipid antibody syndrome.
Also known as: excessive blood clotting, hypercoagulability, hypercoagulability state, hypercoagulable
78 clinical trials for this condition and its sub-types, 12 tagged with Thrombophilia itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Thrombophilia
-
Inherited thrombophilia 0 trials · 28 incl. sub-types
12 sub-types
- Thrombophilia due to thrombin defect 19 trials
- Thrombophilia due to activated protein C resistance 5 trials
- Hereditary antithrombin deficiency 3 trials
- Hereditary thrombophilia due to congenital protein C deficiency 1 trial Sub-types →
- Factor 5 excess with spontaneous thrombosis 0 trials
- Heparin cofactor 2 deficiency 0 trials
- Hereditary thrombophilia due to congenital histidine-rich (poly-L) glycoprotein deficiency 0 trials
- Hereditary thrombophilia due to congenital protein S deficiency 0 trials Sub-types →
- Thrombomodulin-related bleeding disorder 0 trials
- Thrombophilia, X-linked, due to factor 8 defect 0 trials
- Thrombophilia, X-linked, due to factor 9 defect 0 trials
- Thrombophilia, familial, due to decreased release of tissue plasminogen activator 0 trials
-
Thrombotic thrombocytopenic purpura 15 trials · 20 incl. sub-types
2 sub-types
-
Disseminated intravascular coagulation 15 trials
2 sub-types
- Disseminated intravascular coagulation in newborn 0 trials
- Purpura fulminans 0 trials Sub-types →
-
Protein S deficiency 3 trials
1 sub-type
Most studied deeper sub-types
-
Tailored drug regimen shows promise for rare blood disorder
Disease control Stopped earlyThis study tested whether giving the drug caplacizumab based on regular blood tests (ADAMTS13 activity) could improve outcomes for adults with acquired thrombotic thrombocytopenic purpura (aTTP), a rare condition causing dangerous blood clots. The trial enrolled 58 adults and mon…
Phase 2 • Sponsor: University Hospital, Rouen • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Cancer drug combo shows promise for Hard-to-Treat bowel cancer
Disease control Stopped earlyThis study tested a combination of two drugs, atezolizumab and bevacizumab, in 46 people with advanced colorectal cancer that had stopped responding to chemotherapy and had a specific genetic feature called MSI-like. The goal was to see if the treatment could shrink tumors. The s…
Phase 2 • Sponsor: Vall d'Hebron Institute of Oncology • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Tiny study on clotting disorder and artery health ends early
Knowledge-focused Stopped earlyThis study aimed to see if women with thrombophilia (a condition that makes blood clot more easily) have differences in artery function compared to healthy women. Researchers planned to measure blood vessel dilation and other artery health markers. However, the study was terminat…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:04 UTC